VRML: heavily shorted low float with FDA approval, a partner, and money in the bank |
 |
 |
| By Michael Sklar |
| Tuesday, 17 August 2010 13:59 |
 Vermillion, Inc. (VRML : Nasdaq) engage in the discovery, development, and commercialization of diagnostics tests that help physicians to diagnose and treat patients.
The company develops novel diagnostic tests in the fields of oncology, hematology, cardiology, and women’s health with the initial focus on ovarian cancer. Its lead product includes the OVA1 ovarian tumor triage test (the ‘OVA1 Test’), which addresses presurgical identification of women who are at high risk of having a malignant ovarian tumor. Ovarian cancer is an uncontrolled growth of abnormal cells in the ovary or ovaries of the female reproductive system. Ovarian cancer, also called cancer of the ovary, is a very serious cancer and one of the leading causes of death from cancer in women. The estimated new cases and deaths from ovarian cancer in the United States in 2010 is 21,880 new cases and 13,850 deaths according www.cancer.gov, Globally the numbers are approximately 204,000 new cases and 125,000 deaths. On September 11, 2009 Vermillion's lead product the OVA1 ovarian tumor triage test (the OVA1 Test) was cleared by the United States Food and Drug Administration. It went from penny stock to being to a $5+ stock in less than 3 weeks. Over the course of time it went all the way up to $34 and has fallen since then and now is $6+. At its highs Adam Feuerstein from thestreet.com criticized it for being so expensive and i agree with him that it was way to high at the time without showing any results. It was also going through bankruptcy. I thought it was quite dangerous to invest in a bio stock that was so high and filing for bankruptcy even with an FDA approval. In January 2010 it emerged from bankruptcy. They recently came out with their 8k and 10Q which had some interesting positive news.
Currently the outstanding shares are approximately 10.3 million which is considered an extremely low float. It also means that the market cap currently is less than $70 million while the company has $29 million in cash and short term investments. This leaves approx $40 million for what their product is worth? You be the judge but i have seen many Bios that don't have an FDA approval, a major partner, and a great product with a larger market cap. VRML is also waiting for their product to launch in Europe. Disclosure: Long VRML BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
about 18 hours ago
FDA panel votes against Xgeva; Nervous GlaxoSmithKline Pulls Cash Out of Eurozone: Below is a look at some of th... http://t.co/h6kQSAz6
about 1 day ago
Illumina’s Board Unanimously Rejects Roche’s Offer; Shire Announces FDA Approval of Vyvanse®: Below is a look at... http://t.co/L3FZivQV
about 2 days ago
Achillion ($ACHN) hammered after BofA rates to "Underperform" citing no M&A speculation. What we said last month: http://t.co/usWk95O6
about 2 days ago
Medgenics ($MDGN) up 10% on Monday! We first told you about the firm last Friday: http://t.co/aD50CMSH
about 2 days ago
Thinly traded BioLineRx shares move on hepatitis C deal: The shares of thinly traded BioLineRx (NASDAQ:BLRX) soa... http://t.co/ugbuZgNN
about 2 days ago
Orexigen® Announces Agreement From the FDA on a Special Protocol Assessment; Acorda Announces Launch of Generic ... http://t.co/vSt6VrLP
about 3 days ago
$CVM up 17% and technically looks like it may head higher.
about 3 days ago
$ANAC drops after GlaxoSmithKline (GSK) pauses enrollment for its clinical trials of its urinary tract infection drug. http://t.co/yUUSzkUr
Free Phone Trade Alerts
